Trending Stock News

TG Therapeutics, Inc. (TGTX) Reaches $8.10 After 7.00% Down Move; 5 Analysts Bullish Heat Biologics, Inc. (HTBX)

Among 5 analysts covering Heat Biologics (NASDAQ:HTBX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heat Biologics had 7 analyst reports since September 1, 2015 according to SRatingsIntel. As per Friday, January 8, the company rating was initiated by Noble Financial. On Monday, June 20 the stock rating was initiated by Roth Capital with “Buy”. The stock of Heat Biologics, Inc. (NASDAQ:HTBX) earned “Buy” rating by Noble Financial on Wednesday, June 7. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, September 1. The rating was initiated by Griffin on Tuesday, September 12 with “Buy”. The rating was maintained by H.C. Wainwright on Thursday, September 3 with “Buy”. The stock of Heat Biologics, Inc. (NASDAQ:HTBX) earned “Speculative Buy” rating by Cantor Fitzgerald on Thursday, February 4. See Heat Biologics, Inc. (NASDAQ:HTBX) latest ratings:

12/09/2017 Broker: Griffin Rating: Buy New Target: $2.25 Initiate
07/06/2017 Broker: Noble Financial Rating: Buy Maintain

The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) is a huge mover today! The stock decreased 0.61% or $0.05 during the last trading session, reaching $8.1. About 319,947 shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has risen 60.54% since December 5, 2016 and is uptrending. It has outperformed by 43.84% the S&P500.The move comes after 5 months negative chart setup for the $572.28M company. It was reported on Dec, 5 by Barchart.com. We have $7.53 PT which if reached, will make NASDAQ:TGTX worth $40.06M less.

Investors sentiment decreased to 0.78 in Q2 2017. Its down 1.62, from 2.4 in 2017Q1. It is negative, as 4 investors sold Heat Biologics, Inc. shares while 5 reduced holdings. 3 funds opened positions while 4 raised stakes. 3.09 million shares or 13.59% less from 3.57 million shares in 2017Q1 were reported. Geode Capital Mgmt Ltd stated it has 79,837 shares. Sabby Ltd Llc stated it has 2.02 million shares or 0.08% of all its holdings. Bancorp Of Ny Mellon Corp stated it has 13,399 shares or 0% of all its holdings. Blackrock reported 6,395 shares. Vanguard Grp Inc holds 0% of its portfolio in Heat Biologics, Inc. (NASDAQ:HTBX) for 661,388 shares. Franklin Street Advisors Nc invested in 60,500 shares or 0.01% of the stock. Smithfield Trust reported 100 shares or 0% of all its holdings. 1,000 were reported by Royal Savings Bank Of Canada. Sei accumulated 20,500 shares. Northern Trust accumulated 25,304 shares. Deutsche Retail Bank Ag invested in 200 shares. Goldman Sachs Grp has invested 0% in Heat Biologics, Inc. (NASDAQ:HTBX). 9,762 were reported by Morgan Stanley. Two Sigma Limited Com owns 22,925 shares for 0% of their portfolio.

The stock 0.65% or $0 during the last trading session, reaching $0.43. It is down 35.57% since December 5, 2016 and is uptrending. It has outperformed by 18.87% the S&P500.

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the United States. The company has market cap of $15.39 million. The firm develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. It currently has negative earnings. The Company’s product candidates include HS-110 that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase 2 clinical trials for the treatment of non-muscle invasive bladder cancer.

Investors sentiment increased to 2.28 in Q2 2017. Its up 0.25, from 2.03 in 2017Q1. It is positive, as 6 investors sold TG Therapeutics, Inc. shares while 19 reduced holdings. 18 funds opened positions while 39 raised stakes. 33.91 million shares or 12.20% more from 30.22 million shares in 2017Q1 were reported. Susquehanna Grp Llp reported 251,682 shares. 83,508 were accumulated by Raymond James & Associates. Public Employees Retirement Association Of Colorado stated it has 13,349 shares or 0% of all its holdings. Artal Grp Sa owns 500,000 shares or 0.09% of their US portfolio. Segall Bryant & Hamill Ltd Liability Corp holds 0.01% or 53,592 shares. Parametric Portfolio Assocs Lc, Washington-based fund reported 85,612 shares. Wells Fargo & Mn accumulated 54,922 shares. 14,771 are owned by State Board Of Administration Of Florida Retirement Systems. Northern Trust holds 598,626 shares or 0% of its portfolio. Columbus Circle Invsts holds 1.40M shares. Pacad Invest accumulated 800 shares. Ameritas Prns holds 0% or 4,260 shares in its portfolio. Gam Ag, Switzerland-based fund reported 98,600 shares. Pnc Fincl Group Inc Inc reported 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). California Public Employees Retirement System reported 106,400 shares or 0% of all its holdings.

Among 8 analysts covering TG Therapeutics (NASDAQ:TGTX), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 14 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, June 5 by Jefferies. On Wednesday, August 12 the stock rating was reinitiated by H.C. Wainwright with “Buy”. The firm has “Strong Buy” rating by Raymond James given on Wednesday, September 9. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) earned “Hold” rating by Zacks on Wednesday, August 12. Brean Capital reinitiated TG Therapeutics, Inc. (NASDAQ:TGTX) rating on Thursday, October 6. Brean Capital has “Buy” rating and $28 target. Suntrust Robinson initiated the shares of TGTX in report on Friday, May 27 with “Buy” rating. The stock has “Buy” rating by H.C. Wainwright on Tuesday, March 7. The rating was initiated by FBR Capital on Tuesday, December 1 with “Outperform”. The rating was maintained by FBR Capital on Thursday, June 15 with “Buy”. The firm has “Buy” rating by SunTrust given on Friday, May 27.

Since June 16, 2017, it had 0 insider purchases, and 1 insider sale for $665,133 activity. Power Sean A also sold $665,133 worth of TG Therapeutics, Inc. (NASDAQ:TGTX) on Friday, June 16.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $572.28 million. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-HodgkinÂ’s lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

Analysts await TG Therapeutics, Inc. (NASDAQ:TGTX) to report earnings on March, 9. They expect $-0.47 earnings per share, up 2.08% or $0.01 from last year’s $-0.48 per share. After $-0.48 actual earnings per share reported by TG Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -2.08% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *